alexa
Reach Us +1-217-403-9671
Preclinical Evaluation Of A PSMAxCD3 Diabody For Therapy Of Prostate Cancer | 8309
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Preclinical evaluation of a PSMAxCD3 Diabody for therapy of prostate cancer

International Conference and Exhibiton on Pharmaceutical Regulatory Affairs

Patrick Buhler

ScientificTracks Abstracts: JBB

DOI: 10.4172/0975-0851.1000107

Abstract
A lthough prostate cancer is the most commonly diagnosed cancer in men and second leading cancer-related cause of death in the Western Civilization there is currently no curative option for advanced stages. A new approach in cancer therapy has been the retargeting of T-cells to the tumor cells by bispecifi c recombinant antibody fragments, termed diabodies. We have constructed a PSMAxCD3 diabody directed against the prostate specifi c membrane antigen (PSMA) on prostate cancer cells and the epsilon-chain of CD3 on T-cells. In the present study, the eff ectivity of the diabody was characterized in vitro and in vivo. Aft er expression into the periplasm of XL-1 Blue E.coli bacteria, the diabody was purifi ed by Immobilized Metal Affi nity Chromatography (IMAC). For determining the cytotoxic potential, PSMA-positive C4-2 cells were incubated with CD4+ and CD8+ lymphocytes. Lysis of the C4-2 cells was measured by a WST-1 assay. Our study proves that the PSMAxCD3 diabody is very potent in eliminating PSMA-positive pros tate cancer cells by redirected lysis through CD3-positive T-lymphocytes in vitro . In a SCID mouse model with C4-2 xenograft tumors, the diabody together with human peripheral blood lymphocytes effi ciently inhibited tumor growth. Th e results suggest the diabody to be a powerful agent which could contribute to an eff ective new therapy against prostate cancer
Biography
Patrick B?hler has completed his Ph.D at the age of 31 years from Freiburg University and continued to do postdoctoral research as research associate. He has published 19 papers in reputed journals
Top